The U.S. is already grappling with unrelated shortages of medications for children, including pain relievers and antibiotics.
U.S. officials and medical suppliers said in interviews that they were closely monitoring the situation in China and had yet to see any shortages directly linked to the latest wave of infections there. Biden administration officials said they had been coordinating across federal agencies to monitor the supply chain and didn’t anticipate significant shortages, unlike at the start of the pandemic, because of government efforts to bolster U.S. stockpiles and moves by companies to lessen their dependence on China.
“We’re looking a lot for potential early warning signs in the medical supply chain for any kinds of disruptions,” said an administration official. “At this point, we haven’t detected any current or likely disruptions, at least to the flow of drugs or devices or supplies of PPE (personal protective equipment) to the United States given what’s going on in China.”
But health care executives and supply chain analysts warn the impact of China’s latest Covid wave could take months to work its way through the supply chain and much will depend on the trajectory of the pandemic in the coming weeks, something officials in the U.S. have limited insight into given the lack of data from China.
“One major concern throughout the entire pandemic has been that because of China’s zero Covid policy, shutdowns greatly reduced manufacturing capacity in China. This is obviously that type of activity on steroids,” said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota. “This is by far the worst of the supply chain challenges we’ve seen so far in the pandemics from China.”
Potential shortages could range from generic drugs, like antibiotics and blood thinners, to electronic components used in advanced medical devices. Despite efforts over the past two years by the Biden administration to bolster the country’s domestic medical supply chain, the complexity, costs and regulations involved in health care manufacturing has limited companies’ ability to shift production.
“When you have specific intellectual property that’s attached to a specific manufacturer or you have very expensive factory production, which is typical in pharma and critical componentry like integrated circuits, those aren’t flip moves, there’s a lot that goes into that,” said Douglas Kent, executive vice president of corporate and strategic alliances at the Association for Supply Chain Management.
The U.S. imported $3.2 billion in drugs and active pharmaceutical ingredients directly from China in 2020, including antibiotics, antidepressants, birth control pills and drugs for chemotherapy, according to a 2021 supply chain analysis by the White House.
More than a quarter of facilities making the active ingredients in blood thinners for the U.S. and nearly 20% of those making a type of anesthetic are based in China. Drugs imported into the U.S. from other countries, such as India and those in Europe, also get the vast majority of their ingredients from China, the report found.
The U.S. health care system has already been grappling with a range of shortages over the past year as a result of China’s Covid policies that caused factories to shut down and disrupted the flow of goods around the country. Last spring, doctors had to limit medical scans after a GE plant making an imaging agent used in the procedure was shutdown for weeks.
The Health Industry Distributors Association found that shipping delays for medical goods have persisted for the past year in part because of bottlenecks created by China’s rolling Covid disruptions. The group found as many as 10,000 medical containers were delayed an average of 25 days in October.
“While the situation has improved compared to the early stages of Covid back in 2020, the manufacturers and distributors are still facing shortages, long lead times and supply risks, combined with increased operational costs,” said Vijay Mohan, a vice president at o9 Solutions, which provides supply chain management technology to health care companies. “The new wave of Covid that has started to re-emerge will further amplify the challenges.”
There are some early signs of slowdowns at China’s biggest ports and in the completion of manufacturing orders, according to CNBC data. Other shipping data shows ocean crossings have continued to decline. But industry analysts say it will take several more weeks to determine how much of that is from the virus and how much is driven by waning demand from U.S. consumers brought on by other economic drivers.
The lack of data coming out of China about the number and location of infections, the mortality rate and variants has made it particularly difficult for companies to assess where they may run into disruptions. Logistics executives said they have been relying on their network of Chinese contacts and analytical data, which so far haven’t indicated any major issues.
“We have this colossal and unprecedented and very rapidly moving pandemic that is going to be hitting multiple peaks in multiple different geographies with different timings, and we’re a little blind on the data that would begin to give us some more insight into what’s happening,” said Stephen Morrison, director of the Global Health Policy Center at the Center for Strategic and International Studies.
Still, Morrison doesn’t expect the disruptions to be prolonged or widespread because health care companies have already been shifting their operations away from China.
“There’s been a lot of adjusting going on by industry, which has already begun to calculate that in terms of their strategic interests, they needed to lessen their exposure in China and diversify. So it’s a different reality now,” said Morrison. “If this had happened at the front end of the pandemic, the impacts would have been bigger, but we’ve had three years of recalibration.”
Businesses may also have to grapple with the risk that China will divert drugs and medical supplies to meet its own population’s needs, and move away from exporting those goods to other countries.
“If you build stuff that’s needed to keep your people healthy and there’s not enough to go around you’re going to revert to domestic satisfaction. I think that would be a natural response,” said Douglas Kent, executive vice president of corporate and strategic alliances at the Association for Supply Chain Management.
Chinese media reports indicate the country has been running low on items that reduce fevers, such as ibuprofen and acetaminophen, with Chinese companies adjusting production to meet those demands. But U.S. officials said they didn’t anticipate there would be any significant shortages of those medications in the U.S. Johnson & Johnson, which makes Tylenol and Motrin, said it didn’t get any of the active ingredients for those medications from China.
Health care officials say they hope that the U.S. is in a better place to withstand any shocks from China. After hospitals saw shortages of gloves, gowns and masks in the early days of the pandemic, many moved to keep larger stockpiles on hand. Hospitals have also increasingly looked to diversify which countries their essential supplies come from.
“We’ve seen a lot of success up and down the supply chain with ensuring that inventories are where they need to be,” said Kyle MacKinnon, senior director of operational excellence at Premier, which helps health care providers manage their supply chains. “It feels like there’s room to absorb some potential impacts of this. Now down to what degree is kind of harder to put your thumb on due to the potentially very large-scale level of Covid cases.”
- China’s Covid wave threatens another snarl of U.S. medical supply chain - January 8, 2023